These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23512719)

  • 1. Inhibitory effects of azelnidipine tablets on morning hypertension.
    Kario K; Sato Y; Shirayama M; Takahashi M; Shiosakai K; Hiramatsu K; Komiya M; Shimada K
    Drugs R D; 2013 Mar; 13(1):63-73. PubMed ID: 23512719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of sustained blood pressure-lowering effect of azelnidipine guided by self-measured morning and evening home blood pressure: subgroup analysis of the At-HOME study.
    Kario K; Uehara Y; Shirayama M; Takahashi M; Shiosakai K; Hiramatsu K; Komiya M; Shimada K
    Drugs R D; 2013 Mar; 13(1):75-85. PubMed ID: 23519655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine.
    Yamagishi T
    Hypertens Res; 2006 Oct; 29(10):767-73. PubMed ID: 17283863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
    Kimura Y; Kitagawa K; Oku N; Kajimoto K; Kato H; Tanaka M; Sakaguchi M; Hougaku H; Sakoda S; Hatazawa J
    Hypertens Res; 2008 Dec; 31(12):2147-54. PubMed ID: 19139604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y; O'Rourke MF; Hoshide S; Ishikawa J; Shimada K; Kario K
    Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial.
    Takihata M; Nakamura A; Kondo Y; Kawasaki S; Kimura M; Terauchi Y
    PLoS One; 2015; 10(5):e0125519. PubMed ID: 25938807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients.
    Kondo T; Goto R; Sonoda K; Yasuda T; Ono K; Takaki Y; Yatsuda R; Miyamura N; Araki E
    Intern Med; 2010; 49(7):637-43. PubMed ID: 20371952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE.
    Kario K; Ando S; Kido H; Nariyama J; Takiuchi S; Yagi T; Shimizu T; Eguchi K; Ohno M; Kinoshita O; Yamada T
    J Clin Hypertens (Greenwich); 2013 Feb; 15(2):133-42. PubMed ID: 23339732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.
    Takami T; Saito Y
    Vasc Health Risk Manag; 2011; 7():383-90. PubMed ID: 21796252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial.
    Arita M; Hashizume T; Tanigawa K; Yamamoto H; Nishio I
    J Cardiovasc Pharmacol; 1999 Feb; 33(2):186-92. PubMed ID: 10028925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT).
    Fukao K; Shimada K; Hiki M; Kiyanagi T; Hirose K; Kume A; Ohsaka H; Matsumori R; Kurata T; Miyazaki T; Daida H
    Cardiovasc Diabetol; 2011 Sep; 10():79. PubMed ID: 21906391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension.
    Inomata J; Murai H; Kaneko S; Hamaoka T; Ikeda T; Kobayashi D; Usui S; Furusho H; Sugiyama Y; Takata S; Takamura M
    J Hypertens; 2014 Sep; 32(9):1898-904. PubMed ID: 24979307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker].
    Sada T; Saito H
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):539-47. PubMed ID: 14639008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
    Matsui Y; Eguchi K; O'Rourke MF; Ishikawa J; Miyashita H; Shimada K; Kario K
    Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azelnidipine.
    Wellington K; Scott LJ
    Drugs; 2003; 63(23):2613-21; discussion 2623-4. PubMed ID: 14636080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography.
    Ito H; Ishii K; Iwakura K; Nakamura F; Nagano T; Takiuchi S
    Hypertens Res; 2009 Oct; 32(10):895-900. PubMed ID: 19680260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H; Kikuchi F; Ishida T
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.
    Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Fukuda T; Numao T; Shimada K; Kario K
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):394-400. PubMed ID: 17577104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olmesartan with azelnidipine versus with trichlormethiazide on home blood pressure variability in patients with type II diabetes mellitus.
    Ushigome E; Matsumoto S; Oyabu C; Ushigome H; Yokota I; Hasegawa G; Nakamura N; Tanaka M; Yamazaki M; Fukui M
    J Am Soc Hypertens; 2017 Mar; 11(3):140-147. PubMed ID: 28089902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.